Exact Mass: 524.3114034
Exact Mass Matches: 524.3114034
Found 114 metabolites which its exact mass value is equals to given mass value 524.3114034
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
VPGPR Enterostatin
C23H40N8O6 (524.3070660000001)
Enterostatin VPGPR (Val-Pro-Gly-Pro-Arg) is a pentapeptide released from procolipase during fat digestion. In addition to the pancreas, enterostatin-immunoreactive cells are also present in the antrum and proximal small intestine. Enterostatin selectively reduces fat intake, decreases insulin secretion, and also increases energy expenditure by activating brown adipose tissue during high-fat feeding. Enterostatins are pentapeptides derived from the NH2-terminus of procolipase after tryptic cleavage and belong to the family of gut-brain peptides. Enterostatin is generated by the action of trypsin on procolipase in the intestinal lumen. Its structure is highly conserved in evolution, with an amino acid sequence of XPXPR. Three enterostatin sequences, Val-Pro-Asp-Pro-Arg (VPDPR), Val-Pro-Gly-Pro-Arg (VPGPR), and Ala-Pro-Gly-Pro-Arg (APGPR), have been studied extensively and shown to be almost equally effective in their ability to decrease dietary fat preference. Enterostatins are selective inhibitors of appetite, particularly of fat intake. Hyperenterostatinemia in obesity is probably secondary to enterostatin resistance; therefore, the regulatory system is producing more enterostatin to counteract the resistance. This is very similar to hyperinsulinemia and hyperleptinemia in obesity. The diminution in the meal-induced secretion of enterostatin in obesity suggests a delay in the appearance of satiety, leading to increased caloric intake. In rats enterostatin decreases body weight by decreasing fat-calorie intake and increasing the sympathetic firing rate of the nerves in interscapular brown adipose tissue. Enterostatin levels are elevated in the plasma of obese women, and enterostatin secretion is diminished after satiety. Oral administration of enterostatin, however, has no effect on food intake, energy expenditure, or body weight in subjects with a preference for a high-fat diet experiencing a negative energy and fat balance, and the physiology of enterostatin in humans remains to be defined. (PMID: 10084574, 9526102, 8886249) [HMDB] Enterostatin VPGPR (Val-Pro-Gly-Pro-Arg) is a pentapeptide released from procolipase during fat digestion. In addition to the pancreas, enterostatin-immunoreactive cells are also present in the antrum and proximal small intestine. Enterostatin selectively reduces fat intake, decreases insulin secretion, and also increases energy expenditure by activating brown adipose tissue during high-fat feeding. Enterostatins are pentapeptides derived from the NH2-terminus of procolipase after tryptic cleavage and belong to the family of gut-brain peptides. Enterostatin is generated by the action of trypsin on procolipase in the intestinal lumen. Its structure is highly conserved in evolution, with an amino acid sequence of XPXPR. Three enterostatin sequences, Val-Pro-Asp-Pro-Arg (VPDPR), Val-Pro-Gly-Pro-Arg (VPGPR), and Ala-Pro-Gly-Pro-Arg (APGPR), have been studied extensively and shown to be almost equally effective in their ability to decrease dietary fat preference. Enterostatins are selective inhibitors of appetite, particularly of fat intake. Hyperenterostatinemia in obesity is probably secondary to enterostatin resistance; therefore, the regulatory system is producing more enterostatin to counteract the resistance. This is very similar to hyperinsulinemia and hyperleptinemia in obesity. The diminution in the meal-induced secretion of enterostatin in obesity suggests a delay in the appearance of satiety, leading to increased caloric intake. In rats enterostatin decreases body weight by decreasing fat-calorie intake and increasing the sympathetic firing rate of the nerves in interscapular brown adipose tissue. Enterostatin levels are elevated in the plasma of obese women, and enterostatin secretion is diminished after satiety. Oral administration of enterostatin, however, has no effect on food intake, energy expenditure, or body weight in subjects with a preference for a high-fat diet experiencing a negative energy and fat balance, and the physiology of enterostatin in humans remains to be defined. (PMID: 10084574, 9526102, 8886249).
(1R,3aS,5R,10aS,11aS,13aR)-1,2,3,3a,3b,4,5,5a,6,12,13,13a-dodecahydro-3a,6,6,13a-tetramethyl-1-[(1S)-1-((2S)-5-methyl-6-oxo-3,6-dihydro-2H-pyran-2-yl)ethyl]-8-oxo-8H-cyclopenta[5,6]cyclopropa[1,8a]naphtho[2,1-c]oxepin-5-yl acetate|schisanbilactone A
16-acetoxy-22alpha-hydroxy-29-nor-24-methylcycloart-1,4, 24(24a)-trien-3,23-dion-3,4-lactone|4-methylene-neomacrolactone
(21R,23S)-3,26-dioxo-21,23:23,26-diepoxylanosta-8,24-dien-21-yl acetate|omphalocarpoidone
24-acetoxy-18alpha-hydroxy-A(1)-norlupa-2,20(29)-diene-27,28-diolic acid 28-methyl ester 27,18alpha-lactone
His Ile Lys Gln
C23H40N8O6 (524.3070660000001)
His Ile Gln Lys
C23H40N8O6 (524.3070660000001)
His Lys Ile Gln
C23H40N8O6 (524.3070660000001)
His Lys Leu Gln
C23H40N8O6 (524.3070660000001)
His Lys Gln Ile
C23H40N8O6 (524.3070660000001)
His Lys Gln Leu
C23H40N8O6 (524.3070660000001)
His Leu Lys Gln
C23H40N8O6 (524.3070660000001)
His Leu Gln Lys
C23H40N8O6 (524.3070660000001)
His Gln Ile Lys
C23H40N8O6 (524.3070660000001)
His Gln Lys Ile
C23H40N8O6 (524.3070660000001)
His Gln Lys Leu
C23H40N8O6 (524.3070660000001)
His Gln Leu Lys
C23H40N8O6 (524.3070660000001)
Ile His Lys Gln
C23H40N8O6 (524.3070660000001)
Ile His Gln Lys
C23H40N8O6 (524.3070660000001)
Ile Lys His Gln
C23H40N8O6 (524.3070660000001)
Ile Lys Gln His
C23H40N8O6 (524.3070660000001)
Ile Gln His Lys
C23H40N8O6 (524.3070660000001)
Ile Gln Lys His
C23H40N8O6 (524.3070660000001)
Lys His Ile Gln
C23H40N8O6 (524.3070660000001)
Lys His Leu Gln
C23H40N8O6 (524.3070660000001)
Lys His Gln Ile
C23H40N8O6 (524.3070660000001)
Lys His Gln Leu
C23H40N8O6 (524.3070660000001)
Lys Ile His Gln
C23H40N8O6 (524.3070660000001)
Lys Ile Gln His
C23H40N8O6 (524.3070660000001)
Lys Leu His Gln
C23H40N8O6 (524.3070660000001)
Lys Leu Gln His
C23H40N8O6 (524.3070660000001)
Lys Gln His Ile
C23H40N8O6 (524.3070660000001)
Lys Gln His Leu
C23H40N8O6 (524.3070660000001)
Lys Gln Ile His
C23H40N8O6 (524.3070660000001)
Lys Gln Leu His
C23H40N8O6 (524.3070660000001)
Leu His Lys Gln
C23H40N8O6 (524.3070660000001)
Leu His Gln Lys
C23H40N8O6 (524.3070660000001)
Leu Lys His Gln
C23H40N8O6 (524.3070660000001)
Leu Lys Gln His
C23H40N8O6 (524.3070660000001)
Leu Gln His Lys
C23H40N8O6 (524.3070660000001)
Leu Gln Lys His
C23H40N8O6 (524.3070660000001)
Pro Pro Arg Arg
Pro Arg Pro Arg
Pro Arg Arg Pro
Gln His Ile Lys
C23H40N8O6 (524.3070660000001)
Gln His Lys Ile
C23H40N8O6 (524.3070660000001)
Gln His Lys Leu
C23H40N8O6 (524.3070660000001)
Gln His Leu Lys
C23H40N8O6 (524.3070660000001)
Gln Ile His Lys
C23H40N8O6 (524.3070660000001)
Gln Ile Lys His
C23H40N8O6 (524.3070660000001)
Gln Lys His Ile
C23H40N8O6 (524.3070660000001)
Gln Lys His Leu
C23H40N8O6 (524.3070660000001)
Gln Lys Ile His
C23H40N8O6 (524.3070660000001)
Gln Lys Leu His
C23H40N8O6 (524.3070660000001)
Gln Leu His Lys
C23H40N8O6 (524.3070660000001)
Gln Leu Lys His
C23H40N8O6 (524.3070660000001)
Arg Pro Pro Arg
Arg Pro Arg Pro
Arg Arg Pro Pro
VPGPR Enterostatin
C23H40N8O6 (524.3070660000001)
22-[(2R)-1-hydroxy-3-phosphonooxypropan-2-yl]oxy-22-oxodocosanoic acid
tert-butyl 4-ethyl-4-[[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]pentan-2-yl]carbamoyloxy]piperidine-1-carboxylate
C26H44N4O7 (524.3209833999999)
(2R)-4-amino-2-[3-[[(3R,5R,7S,8E,10E,12E)-3-amino-5-hydroxy-7-methoxyoctadeca-8,10,12-trienoyl]amino]propanoylamino]-4-oxobutanoic acid
C26H44N4O7 (524.3209833999999)
[3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (Z)-nonadec-9-enoate
1-(9Z-nonadecenoyl)-glycero-3-phospho-(1-sn-glycerol)
21-hydroxy-4-(hydroxymethyl)-3-(2-hydroxypropyl)-6,10,16,20-tetramethyl-24-oxapentacyclo[20.2.1.0¹,⁶.0¹¹,²⁰.0¹⁴,¹⁹]pentacosa-4,8,12,21-tetraene-23,25-dione
(6r)-6-[(1r,2s,3ar,5ar,9as,11ar)-2-(acetyloxy)-3a,6,6,9a,11a-pentamethyl-7,10-dioxo-1h,2h,3h,4h,5h,5ah,11h-cyclopenta[a]phenanthren-1-yl]-2-methylhept-2-enoic acid
2-hydroxy-2,4-dimethyl-5-[(5e,7e,9e,11e)-2,4,14-trihydroxy-9,13,15-trimethyl-17-phenylheptadeca-5,7,9,11-tetraen-1-yl]furan-3-one
bisacutifolone c
{"Ingredient_id": "HBIN018600","Ingredient_name": "bisacutifolone c","Alias": "NA","Ingredient_formula": "C32H44O6","Ingredient_Smile": "CC1CCC2(C1(C(=O)C=C(C2C)C3CCCC4=C3C(=O)C5(C(CCC5(C4C)C)C)C(=O)OC)C(=O)OC)C","Ingredient_weight": "524.7 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "2434","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "15479053","DrugBank_id": "NA"}